electroCore (ECOR) Q3 2024 earnings summary

Executive summary

• Achieved eighth consecutive record revenue quarter, with Q3 2024 revenue of $6.6 million, up 45% year-over-year, driven by growth in VA/DoD and Truvaga products.

• Net loss for Q3 2024 narrowed to $2.5 million, a 38% improvement from Q3 2023, reflecting higher sales and reduced R&D spending.

• Gross margin held steady at 84%, with disciplined operating expenses and progress toward positive cash flow and GAAP profitability.

• Majority of revenue continues to come from VA/DoD, with ongoing expansion in government and commercial channels and strong growth in direct-to-consumer markets.

• Company expects to fund operations for at least 12 months based on current cash position and reduced net loss.

Financial highlights

• Q3 2024 net sales were $6.6 million, a 45% increase from $4.5 million in Q3 2023; year-to-date revenue reached $18.1 million, up 67%.

• Gross profit for Q3 2024 was $5.5 million, with gross margin stable at 84%.

• GAAP net loss for Q3 2024 was $2.5 million ($0.31/share), improved from $4 million ($0.68/share) in Q3 2023.

• Adjusted EBITDA net loss improved to $2.1 million in Q3 2024 from $3 million in Q3 2023.

• Cash and equivalents at September 30, 2024, totaled $13.2 million, up from $10.6 million at year-end 2023.

Outlook and guidance

• Expect continued progress toward positive Adjusted EBITDA and GAAP profitability as revenue grows, with further sequential declines in cash used in operations.

• Project positive cash flow from operations early next year, leveraging current financial resources.

• Majority of 2024 revenue expected from VA/DoD; TAC-STIM product revenue may fluctuate quarter to quarter.

• Ongoing investments planned in sales and marketing to support commercial growth.

• No formal top-line guidance provided, but internal review of guidance policy is ongoing.